TY - JOUR
T1 - A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making
AU - Mikl, Veronika
AU - Baltic, Dejan
AU - Czypionka, Thomas
AU - Degelsegger-Márquez, Alexander
AU - Forgó, Nikolaus
AU - Gouya-Lechner, Ghazaleh
AU - Herzog, Arnold
AU - Mraz, Bernhard
AU - Stamm, Tanja
AU - Zeitlinger, Markus
AU - Ostermann, Herwig
AU - Klimek, Peter
AU - Lumenta, David Benjamin
AU - Scharinger, Robert
AU - Strassnig, Michael
AU - Pleiner-Duxneuner, Johannes
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Real-world data (RWD) can provide intel (real-world evidence, RWE) for research and development, as well as policy and regulatory decision-making along the full spectrum of health care. Despite calls from global regulators for international collaborations to integrate RWE into regulatory decision-making and to bridge knowledge gaps, some challenges remain. In this work, we performed an evaluation of Austrian RWD sources using a multilateral query approach, crosschecked against previously published RWD criteria and conducted direct interviews with representative RWD source samples. This article provides an overview of 73 out of 104 RWD sources in a national legislative setting where major attempts are made to enable secondary use of RWD (e.g. law on the organisation of research, "Forschungsorganisationsgesetz"). We were able to detect omnipresent challenges associated with data silos, variable standardisation efforts and governance issues. Our findings suggest a strong need for a national health data strategy and data governance framework, which should inform researchers, as well as policy- and decision-makers, to improve RWD-based research in the healthcare sector to ultimately support actual regulatory decision-making and provide strategic information for governmental health data policies.
AB - Real-world data (RWD) can provide intel (real-world evidence, RWE) for research and development, as well as policy and regulatory decision-making along the full spectrum of health care. Despite calls from global regulators for international collaborations to integrate RWE into regulatory decision-making and to bridge knowledge gaps, some challenges remain. In this work, we performed an evaluation of Austrian RWD sources using a multilateral query approach, crosschecked against previously published RWD criteria and conducted direct interviews with representative RWD source samples. This article provides an overview of 73 out of 104 RWD sources in a national legislative setting where major attempts are made to enable secondary use of RWD (e.g. law on the organisation of research, "Forschungsorganisationsgesetz"). We were able to detect omnipresent challenges associated with data silos, variable standardisation efforts and governance issues. Our findings suggest a strong need for a national health data strategy and data governance framework, which should inform researchers, as well as policy- and decision-makers, to improve RWD-based research in the healthcare sector to ultimately support actual regulatory decision-making and provide strategic information for governmental health data policies.
KW - Data quality
KW - Data quality criteria
KW - Data quality recommendations
KW - FAIR data principles
KW - Gesellschaft für Pharmazeutische Medizin
KW - GPMed
KW - Health data strategy
KW - Health data use
KW - Healthcare decision-making
KW - Pharmaceutical research
KW - Quality criteria for RWD in health care
KW - Real-world data
KW - Real-world evidence
KW - Secondary use of health data
UR - https://www.scopus.com/pages/publications/85191747698
U2 - 10.1038/s41598-024-59475-9
DO - 10.1038/s41598-024-59475-9
M3 - Article
SN - 0028-0836
VL - 14
JO - Nature
JF - Nature
IS - 1
M1 - 9751
ER -